Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Patel explained that while dermatologic risk stratification focuses on recurrence potential to guide surgical margins, oncologic staging assesses metastatic risk and mortality. For medical oncologists, Patel advised developing relationships with dermatology to jointly discuss moderately and highly rated cSCC disease under either system early, as these aggressive tumors will likely recur and ultimately need systemic therapy. Luke asked Barker to describe factors determining tumor resectability. Barker emphasized starting with a thorough history and physical to guide tests selection while getting specialist input. He explained resection candidacy involves both tumor considerations and acceptable patient trade-offs between surgery/radiation morbidity and disease control. Barker stated when curative-intent surgery and radiation are declined, systemic therapy is considered, often initially in the neoadjuvant setting, which requires additional study.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More